Bacterial and Viral Specimen Collection Market (By Product: Bacterial Specimen Collection, Viral Specimen Collection; By Application: Diagnostics, Research; By End-use: Hospitals & Clinics, Home Test, Research Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global bacterial and viral specimen collection market size was USD 40.31 billion in 2023, calculated at USD 46.01 billion in 2024 and is expected to reach around USD 151.41 billion by 2033. The market is expanding at a solid CAGR of 14.15% over the forecast period 2024 to 2033. The rise in rare diseases in human beings has increased the demand for bacterial & viral specimen collection in diagnostic labs, which is estimated to drive the growth of the global bacterial and viral specimen collection market over the forecast period.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. bacterial and viral specimen collection market size was exhibited at USD 12.98 billion in 2023 and is projected to be worth around USD 49.64 billion by 2033, poised to grow at a CAGR of 14.35% from 2024 to 2033.
North America witnessed the largest revenue share for the year 2023. Increasing government initiatives and profitable policies for bacterial & viral specimen collection in the North American region are estimated to drive the growth of the bacterial and viral specimen collection Market over the forecast period. For instance, in June 2024, according to the data published by the American Medical Association, it was estimated that the government laboratories would be paid a good charge for specimen collection and transport. The advanced infrastructure required for specimen collection has been developed in American government hospitals. Government college and university students in North America will be trained free of cost for 3 months for specimen collection and testing under the newly launched policy by the government of the U.S.
Asia Pacific is estimated to be the fastest-growing during the forecast period, significantly driven by the launch of a new product for the diagnosis of several diseases in the Asia Pacific region to meet high clinical needs, which indirectly raised the demand for bacterial & viral specimen collection. For instance, in January 2024, QIAGEN, a global provider of diagnostic solutions, announced the launch of the two syndromic testing panels for its QIAstat-Dx instruments in India, including the Encephalitis/ Meningitis Panel and the Gastrointestinal Panel 2. With the Central Drugs Standard Control Organization's (CDSCO) regulatory certification of the QIAstat-Dx system, healthcare providers in India are allowed to diagnose patients by collecting specimens more quickly, correctly, and easily. In under one hour, the QIAstat-Dx Gastrointestinal Panel 2 may identify 22 clinically important viral, parasite, and bacterial pathogens that cause the majority of gastrointestinal infections. Comparing this panel to standard microbiological testing, which frequently necessitates incubating samples for at least 24 hours and up to 10 days, reveals considerable advantages.
The specimen management procedure plays a crucial role in producing accurate, meaningful, and clinically relevant microbiology laboratory results. The quality of the samples and how they are processed in the microbiology lab still have a significant impact on how the results of the microbiological analysis are interpreted and how accurate they are. Crucial aspects of the diagnostic procedure include the type of specimen, when to collect the sample, and how to sample, store, and transport it. The need to examine and update all sample processing procedures arises from the development of novel laboratory techniques for uncommon diseases.
The bacterial and viral Specimen collection market plays an important role in carrying out tests to identify whether the patient is infected by bacteria or a virus. The successful laboratory diagnosis of microbial infection depends on numerous factors, beginning with an appropriately collected sample. Adequate specimen transport collection and selection are all crucial to ensure that a specimen is representative of the disease process and slightly contaminated with microorganisms present in adjacent tissues. Clinical microbiologists have started to emphasize specimen management as a procedure that is essential to a successful diagnosis.
Report Coverage | Details |
Market Size by 2033 | USD 151.41 Billion |
Market Size in 2023 | USD 40.31 Billion |
Market Size in 2024 | USD 46.01 Billion |
Market Growth Rate from 2024 to 2033 | CAGR of 14.15% |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | Product, Application, End-use, and Regions |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Increasing prevalence of infectious viral diseases
The rise in the prevalence of infectious viral diseases has increased the demand for bacterial & viral specimen collection, which is estimated to drive the growth of the global bacterial and viral specimen collection market over the forecast period. For instance, On June 9, 2024, according to the data published by the World Health Organization (WHO), an intergovernmental organization, it was estimated that in the last 28 days, the number of COVID-19 cases has increased by 4,528 globally.
Challenges and limitations associated with the bacterial & viral specimen collection
Certain limitations, such as the possibility of bacteria becoming resistant to bacteriophages (BPs), issues with selecting the accurate and effective bacteriophages to treat different bacterial infections, and lack of skilled professionals, have been found to hamper the growth of the global bacterial and viral specimen collection market over the forecast period. For instance, in June 2023, according to the data published by the National Center for Biotechnology Information, it was estimated that bacteria have the ability to develop many ways to avoid viral infections, which may lead to the emergence of bacterial resistance against BPs.
These include phage adherence to the bacterial pathogen being prevented by chemicals secreted from hiding, changing, or losing receptors, activating mechanisms to prevent phage Deoxyribonucleic acid (DNA) injection into cells, and inhibiting phage replication and release. The Deoxyribonucleic acid (DNA) of lyticogenic phages is incorporated into the bacterial genome. As such, they may serve as conduits for the horizontal transfer of genetic material and contribute to the spread of genes that confer antibiotic resistance (ARGs). It is theoretically possible for new microorganisms or even more resilient bacteria to arise as a result of transduction.
Increasing launch of microbiology laboratory
The key bacterial and viral specimen collection market players are focused on launching the new microbiology laboratory, which has raised the demand for bacterial & specimen collection and created a lucrative opportunity for the growth of the global bacterial & viral specimen collection market. For instance, in January 2023, SGS, a company focused on manufacturing and developing testing and inspection material, announced the launch and start of the new laboratory facilities for microbiology testing in Phoenix, Arizona, U.S., named Biosafety Level-2 microbiology lab. The Biosafety Level-2 microbiology lab delivers a wide range of microbial testing facilities and services to clients of hand sanitizer and antibacterial hand soap manufacturing industries. Therefore, the launch of the new microbiology laboratory has increased the demand for bacterial & specimen collection kits.
The bacterial specimen collection held the dominating share of the bacterial & specimen collection market in 2023 on account of increasing approval of the product by the regulatory bodies for import and export.
The viral specimen collection segment has witnessed the fastest growth in the year 2023 on account of the increasing launch of the new viral specimen transportation media.
The diagnosis segment held the largest share of the global bacterial and viral specimen collection market in 2023. The increasing prevalence of viral infectious diseases is estimated to fuel the growth of the diagnosis segment over the forecast period. For instance, in April 2024, the World Health Organization, an intergovernmental organization, claimed that the number of patients' lives lost due to viral hepatitis is increasing. 1.3 million deaths annually are caused by hepatitis, making it the second most common infectious cause of death worldwide, right behind tuberculosis, which is the ranks first infectious killer.
The research, which was presented at the World Hepatitis Summit, emphasizes that testing and treatment coverage rates have stagnated in spite of improved diagnostic and treatment instruments and falling product costs. However, if quick action is taken, achieving the World Health Organization (WHO) elimination target by 2030 should still be possible. According to the same source, it was estimated that on an everyday basis, 3500 people become victims of death globally due to hepatitis C and hepatitis B infections.
The hospitals & clinics segment held the largest share of the global bacterial and viral specimen collection market in 2023. The increase in new disease breakouts has raised the demand for bacterial & viral specimen collection in hospitals & clinics. For instance, in May 2024, the International Health Regulations (IHR) National Focal Point (NFP), a national office or center for India, reported to the World Health Organization an incidence of human infection with avian influenza A(H9N2) virus diagnosed in a hospital of West Bengal state in India. Due to the youngster's ongoing acute respiratory distress, repeated high-grade fever, and abdominal cramps, the patient was admitted to the pediatric intensive care unit (ICU) of a nearby hospital on February 1, 2024.
Viral pneumonia-induced post-infectious bronchiolitis was the diagnosis made for the patient. After the first case in 2019, this is the second case of avian influenza A(H9N2) in humans that the World Health Organization has been informed from India. After making a full recovery, the child was released from the hospital. A human infection brought on by a novel influenza A virus subtype is considered an occurrence with a high potential impact on public health and needs to be reported to the World Health Organization (WHO).
Segments Covered in the Report
By Product
By Application
By End-use
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Bacterial and Viral Specimen Collection Market
5.1. COVID-19 Landscape: Bacterial and Viral Specimen Collection Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Bacterial and Viral Specimen Collection Market, By Product
8.1. Bacterial and Viral Specimen Collection Market Revenue and Volume, By Product, 2024-2033
8.1.1 Bacterial Specimen Collection
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Viral Specimen Collection
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Bacterial and Viral Specimen Collection Market, By Application
9.1. Bacterial and Viral Specimen Collection Market Revenue and Volume, By Application, 2024-2033
9.1.1. Diagnostics
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Research
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Bacterial and Viral Specimen Collection Market, By End-use
10.1. Bacterial and Viral Specimen Collection Market Revenue and Volume, by March, 2024-2033
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Home Test
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Research Laboratories
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Bacterial and Viral Specimen Collection Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.1.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.1.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.2.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.2.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.3.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.3.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.4.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.5.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, By Product (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, By Application (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, By End-use (2021-2033)
Chapter 12. Company Profiles
12.1. Puritan Medical Products
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. COPAN Diagnostics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Becton, Dickinson and Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Thermo Fisher Scientific, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Quidel Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Longhorn Vaccines and Diagnostics, LLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pretium Packaging
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Trinity Biotech
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Medical Wire & Equipment
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. HiMedia Laboratories
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client